6917 Stock Overview
A biopharmaceutical company, engages in developing novel drug delivery platform technologies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Andros Pharmaceuticals Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$16.05 |
| 52 Week High | NT$26.75 |
| 52 Week Low | NT$15.40 |
| Beta | 0 |
| 11 Month Change | -6.69% |
| 3 Month Change | -13.24% |
| 1 Year Change | -39.77% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -49.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6917 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -3.3% | 1.4% | 0.8% |
| 1Y | -39.8% | 7.5% | 30.3% |
Return vs Industry: 6917 underperformed the TW Pharmaceuticals industry which returned 7.5% over the past year.
Return vs Market: 6917 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 6917 volatility | |
|---|---|
| 6917 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6917's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6917's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | n/a | www.andros.com.tw |
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain.
Andros Pharmaceuticals Co.,Ltd Fundamentals Summary
| 6917 fundamental statistics | |
|---|---|
| Market cap | NT$558.09m |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6917 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6917 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 6917 perform over the long term?
See historical performance and comparison